Profluent and Eli Lilly Announce $2.25 Billion Partnership for AI-Designed Genetic Medicines on April 28, 2026 AI protein design eli lilly Gene Modification genetic medicines pharmaceutical partnership Profluent recombinase +
Galux Raises $29M Series B for AI Protein Design on February 10, 2026 AI protein design Funding Galux MEMO1 gene methionine partnerships Series B SMPX gene +
Innovative Solutions for Difficult-to-Express Proteins: Cell-Free Systems and AI-Driven Advances on January 02, 2026 AI protein design Alternative Cell-free protein Difficult-to-Express Proteins Gene Expression In Vitro [Publication Type] +